



ARTHRAMIDVET®

A ONE HEALTH SOLUTION

Proven Science, Proven Results

One Health is a strategy that emphasizes the collaborative efforts of multiple disciplines working locally, nationally, and globally, to achieve optimal health for humans, animals, and the environment.

Contura International A/S (Contura), the manufacturer of ArthramidVet®, is proud to be a One Health company focused on hydrogel solutions for a range of conditions that impact both humans and animals. Contura provides a wide range of 2.5% injectable polyacrylamide (2.5 iPAAG) products and is dedicated to enhancing the quality of life for patients of all species. Backed by more than 20 years of research and development, Contura is committed to delivering the highest quality products for patients and those who care for them.

One Hydrogel. One Health.

Composed of 3 separate business units, Contura's innovation has led to the development of four unique products to treat numerous species and conditions. Although they may have different indications, our 2.5 iPAAG products are united by a shared foundation.

While each product has a different indication, the common bonds of our 2.5 iPAAG tie them together. They boast a long-standing history of safety, efficacy, and quality of life improvement for human and animal patients worldwide.

ARTHRAMIDVET®

BULKAMID®

ARTHROSAMID®

AQUAMID®

*Discontinued 2024

Hydrogels for Life

Committed to providing innovative 2.5 iPAAG technologies that make a meaningful and lasting difference to patients lives everywhere.



A One Health Portfolio

ArthramidVet®

Indicated for the treatment of non-infectious causes of joint disease in horses and dogs, ArthramidVet® has been used for more than a decade by veterinarians across the world. With studies supporting 24 months of efficacy, ArthramidVet® provides a lasting benefit to joint function and patient quality of life.¹

Arthrosamid®

Intended for symptomatic treatment of adult human patients with knee osteoarthritis, Arthrosamid® is changing the standard of care for knee osteoarthritis. Arthrosamid® is approved for use in the UK, EU and Canada. Significant improvements in pain, stiffness and function lasting up to 36 months are reported following Arthrosamid® injection.²


Bulkamid®

Intended to be used as a urethral bulking agent for the treatment of female urinary incontinence where the stress component is significant. With a robust safety profile, Bulkamid® has shown clinical results and durability for up to at least 7 years.³ Bulkamid® is now offered by Axonics®.

Aquamid®

*Discontinued 2024

Indicated for use in soft tissue augmentation for reconstructive purposes, including corrections of facial lipoatrophy. With over 20 years of safety and efficacy data and numerous publications, Aquamid has consistently delivered positive patient results and lead to the development of additional 2.5 iPAAG indications.



Scanning electron microscope images of fresh 2.5 iPAAG showing the typical uniform 3-D cross-linked structure

Scan the QR codes to learn more about our hydrogel portfolio.



1.Tnibar, A., Schougaard, H., Camitz, L., Rasmussen, J., Koene, M., Jahn, W., & Markussen, B. (2015). An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up. *Acta veterinaria Scandinavica*, 57(1), 20. <https://doi.org/10.1186/s13028-015-0110-6>
2. Hub. (2023, April 15). New 3 year data demonstrates the long-term efficacy of Arthrosamid® (2.5% injectable polyacrylamide hydrogel). Hub Publishing. <https://hubpublishing.co.uk/new-3-year-data-demonstrates-the-long-term-efficacy-of-arthrosamid-2-5-injectable-polyacrylamide-hydrogel/>
3.Brosche, T., Kuhn, A., Lobodasch, K., & Sokol, E. R. (2021). Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence. *Neurourology and urodynamics*, 40(1), 502–508. <https://doi.org/10.1002/nuu.24589>
4.Pallua, N., & Wolter, T. P. (2010). A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients. *Plastic and reconstructive surgery*, 125(6), 1797–1804. <https://doi.org/10.1097/PRS.0b013e3181d18158>